Oryzon Genomics (XMAD:ORY) Cyclically Adjusted Book per Share: €1.39 (As of Mar. 2026)


XMAD:ORY Oryzon Genomics SA XMAD:ORY
31 GF Score
Price €3.18
View Full Analysis

What is Oryzon Genomics Cyclically Adjusted Book per Share?

Oryzon Genomics XMAD:ORY +1.47% 31 Cyclically Adjusted Book per Share is €1.39 as of Mar. 2026. GuruFocus rates XMAD:ORY with a GF Score™ of 31/100.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Oryzon Genomics's adjusted book value per share for the three months ended in Mar. 2026 was €1.518. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €1.39 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Oryzon Genomics's average Cyclically Adjusted Book Growth Rate was 3.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2026-06-28), Oryzon Genomics's current stock price is €3.18. Oryzon Genomics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was €1.39. Oryzon Genomics's Cyclically Adjusted PB Ratio of today is 2.29.

During the past 12 years, the highest Cyclically Adjusted PB Ratio of Oryzon Genomics was 2.29. The lowest was 0.00. And the median was 0.00.


Oryzon Genomics  (XMAD:ORY) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Oryzon Genomics's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=3.18/1.39
=2.29

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 12 years, the highest Cyclically Adjusted PB Ratio of Oryzon Genomics was 2.29. The lowest was 0.00. And the median was 0.00.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Oryzon Genomics Cyclically Adjusted Book per Share Related Terms


Oryzon Genomics Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Oryzon Genomics's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oryzon Genomics Cyclically Adjusted Book per Share Chart

Oryzon Genomics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 1.34 1.38

Oryzon Genomics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.34 1.36 1.36 1.38 1.39

XMAD:ORY vs VRTX, REGN, ALNY: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Oryzon Genomics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oryzon Genomics Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oryzon Genomics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Oryzon Genomics's Cyclically Adjusted PB Ratio falls into.


XMAD:ORY
31GF Score
Oryzon Genomics SA XMAD:ORY
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Oryzon Genomics Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Oryzon Genomics's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=1.518/128.4016*128.4016
=1.518

Current CPI (Mar. 2026) = 128.4016.

Oryzon Genomics Quarterly Data

Book Value per Share CPI Adj_Book
201606 0.889 100.333 1.138
201609 0.865 99.737 1.114
201612 0.817 101.842 1.030
201703 0.775 100.896 0.986
201706 1.118 101.848 1.409
201709 1.048 101.524 1.325
201712 1.042 102.975 1.299
201803 0.994 102.122 1.250
201806 1.032 104.165 1.272
201809 0.879 103.818 1.087
201812 1.180 104.193 1.454
201903 1.133 103.488 1.406
201906 1.159 104.612 1.423
201909 1.367 103.905 1.689
201912 1.366 105.015 1.670
202003 1.135 103.469 1.408
202006 1.471 104.254 1.812
202009 1.456 103.521 1.806
202012 1.455 104.456 1.789
202103 1.383 104.857 1.694
202106 1.403 107.102 1.682
202109 0.001 107.669 0.001
202112 1.353 111.298 1.561
202203 1.330 115.153 1.483
202206 1.313 118.044 1.428
202209 1.285 117.221 1.408
202212 1.311 117.650 1.431
202303 1.264 118.948 1.364
202306 1.367 120.278 1.459
202309 1.337 121.343 1.415
202312 1.362 121.300 1.442
202403 1.313 122.762 1.373
202406 1.369 124.409 1.413
202409 1.372 123.121 1.431
202412 1.353 124.753 1.393
202503 1.102 125.531 1.127
202506 1.498 127.251 1.512
202509 1.480 126.842 1.498
202512 1.525 128.402 1.525
202603 1.518 128.402 1.518

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of €1.39 mean?
Oryzon Genomics (XMAD:ORY) has a Cyclically Adjusted Book per Share of €1.39 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Oryzon Genomics and its competitors.
Is Oryzon Genomics' Cyclically Adjusted Book per Share too high?
Oryzon Genomics' current Cyclically Adjusted Book per Share is €1.39. Overall, Oryzon Genomics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Oryzon Genomics' Cyclically Adjusted Book per Share compare to VRTX and REGN?
Oryzon Genomics' Cyclically Adjusted Book per Share of €1.39 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Oryzon Genomics and its competitors. Oryzon Genomics's current Cyclically Adjusted Book per Share is €1.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oryzon Genomics stock overvalued right now?
Oryzon Genomics (XMAD:ORY) has a current Cyclically Adjusted Book per Share of €1.39. The current Cyclically Adjusted Book per Share is €1.39. Oryzon Genomics' overall GF Score™ is 31/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Oryzon Genomics (XMAD:ORY), the current Cyclically Adjusted Book per Share is €1.39 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Oryzon Genomics Business Description

Other Exchanges ORYZF:USA0RDB:UKORN:Germany
Address Sant Ferran 74, Cornellà de Llobregat, Barcelona, ESP, 08940
Oryzon Genomics SA is a clinical stage biopharmaceutical company and engaged in the development of epigenetics-based therapeutics. It is engaged in the field of epigenetic medicine and in the development of therapeutic, biological solutions for cancer and neurodegenerative diseases.
31GF Score

Get the complete analysis for XMAD:ORY

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.18
Price